Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 3/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL8378844 | 0.85 | TDP1 (0.50) | LMNABLMPMP22SMN1; SMN2HTT | |
| Acetone SCHEMBL5003447 | 0.85 | SMN1; SMN2 (0.55) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| Biphenyl SCHEMBL2670012 | 0.84 | MAPT (0.61) | LMNAALOX15BLMPMP22SMN1; SMN2 | |
| Biphenyl SCHEMBL27396598 | 0.82 | MAPT (0.58) | LMNAALOX15BLMPMP22SMN1; SMN2 | |
| SCHEMBL29257169 | 0.82 | TDP1 (0.67) | LMNAALOX15BLMPMP22SMN1; SMN2 | |
| Butanedione SCHEMBL9371536 | 0.81 | TSHR (0.54) | SMN1; SMN2HTTL3MBTL1MAPTHSD17B1 | |
| Acetic Acid SCHEMBL2473166 | 0.81 | SMN1; SMN2 (0.57) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| Acetic Acid SCHEMBL751998 | 0.79 | SMN1; SMN2 (0.55) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL28592894 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTL3MBTL1MAPTHSD17B1 | |
| SCHEMBL9577036 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTL3MBTL1MAPTHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117945351-A | Working solution for producing hydrogen peroxide by anthraquinone process | 中国石油化工股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-103153950-B | Serotonin reuptake inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-11-25 | — | — | CN | claimed |
| EP-2627630-B1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2014-12-31 | — | — | EP | claimed |
| US-8729119-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2014-05-20 | — | — | US | claimed |
| US-20130253013-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2013-09-26 | — | — | US | claimed |
| EP-2627630-A1 | SEROTONIN REUPTAKE INHIBITORS | Theravance, Inc. (US) | 2013-08-21 | — | — | EP | claimed |
| US-8471040-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2013-06-25 | — | — | US | claimed |
| CN-103153950-A | Serotonin reuptake inhibitor | THERAVANCE INC | 2013-06-12 | — | — | CN | claimed |
| WO-2012051103-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2012-04-19 | — | — | WO | claimed |
| US-20120088799-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | claimed |
| US-20060148789-A1 | Novel diazabicyclic aryl derivatives | NEUROSEARCH A/S (DK) | 2006-07-06 | — | — | US | claimed |
| CN-1738820-A | Novel diazabicyclic aryl derivatives | NEUROSEARCH AS (DK) | 2006-02-22 | — | — | CN | claimed |
| EP-1599476-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2005-11-30 | — | — | EP | claimed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | claimed |
| CN-1665800-A | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2005-09-07 | — | — | CN | claimed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2004076453-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2004-09-10 | — | — | WO | claimed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | LMNA 4410/4885ALOX15 348/4885BLM 1706/4885 |
| US-20130253013-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | LMNA 2528/4885ALOX15 3239/4885BLM 3071/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | LMNA 4320/4885ALOX15 385/4885BLM 2110/4885 |
| US-20120088799-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | LMNA 2528/4885ALOX15 3239/4885BLM 3071/4885 |
| US-20060148789-A1 | Novel diazabicyclic aryl derivatives | CHRNA6, CHRNA10, CHRNA2 | LMNA 2513/4885ALOX15 1362/4885BLM 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.